Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC

Vectura Group PLC (LON:VEC), Hikma Pharmaceuticals Plc (LON:HIK) and Indivior PLC (LON:INDV) are three top plays on the biotech boom.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After a record-breaking 2014, 2015 is shaping up to be another momentous year for biotech. 

During the first few months of 2015 to the beginning of March, the value of M&A deals in the pharma sector hit $59.3bn, up 94% year on year. Over the past four weeks, at least four more multi-billion dollar deals have been announced. 

And for investors that are looking to play this trend, three of the best picks are Vectura (LSE: VEC), Hikma Pharmaceuticals (LSE: HIK) and Indivior (LSE: INDV). 

In demand 

Early-stage respiratory drug specialist Vectura has struggled to impress over the past five years, but the company is finally starting to show signs of progress. 

The company has sealed a number of deals with key partners over the past 12 months. These include a collaboration deal for the company’s latest asthma product, VR506, signed with an undisclosed US partner. And a global development and licence agreement with Janssen Biotech Inc, a unit of US healthcare group Johnson & Johnson.

What’s more, Vectura has nine products in its pipeline, which are expected to come to market during 2021.  

As Vectura’s deals add up, City analysts expect the group to report a pre-tax profit of £1.6m this year — its first profit for several years. Then, during 2016 and 2017, City analysts expect Vectura’s earnings to take off. Analysts expect the company’s earnings to expand by 200% during 2016 and 260% during 2017.

Generic producer 

Generic drug production is one of the biotech market’s hottest industries. Indeed, as consumers around the world switch to low-cost generic drugs to combat ever-higher medical bills, generic producers have struggled to meet demand.

Hikma is one of the companies that has been able to benefit from this trend. 

Over the past five years Hikma’s earnings have tripled and the company has recently been promoted to the FTSE 100 index. That said, earnings are set to contract by 7% this year, although during 2016, City analysts believe that Hikma’s earnings will rebound by 18%, more than making up for this year’s decline.

Hikma is currently trading at a 2016 P/E of 19.7, compared to the biotech sector average P/E of 31.

Unwanted spin-off

Reckitt Benckiser‘s spin-off Indivior is probably one of the cheapest biotech companies in the world. After failing to find a buyer for Indivior, Reckitt spun the company off at an astonishingly low valuation, due to the fact that Indivior’s sales were coming under pressure from generic competitors.

Unfortunately, City analysts expect the company’s sales to remain under pressure for some time.  Revenue fell 8% during 2014 and is set to fall another 4% this year. Nevertheless, due to these low expectations Indivior is trading at a forward P/E of 14.2, around half the sector’s average valuation. The company is set to offer a dividend yield of 3% this year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves dose not own any share mentioned here. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

These were the FTSE 100’s dogs and stars in February

The FTSE 100 limped along last month, but some Footsie shares soared while others slumped. Here are February's winners and…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

This £43bn of passive income is up for grabs today!

As a lover of passive income, I'm always on the lookout for extra cash. The good news is that these…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Is this my once-in-a-decade chance to buy these 2 beaten-down UK shares before they rocket?

The FTSE 100 has had a bumpy ride but these two UK shares have had it bumpier. Could now be…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

£6k bought me 3,093 shares in this overlooked FTSE passive income stock yielding 9.1% a year

This FTSE 100 dividend stock pays one of the most generous levels of passive income on the index, yet often…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

With a 5.35% yield does it matter if the National Grid share price never rises again?

The National Grid share price will never fly to the stars, but given the regular supply of dividends it offers,…

Read more »

Risk reward ratio / risk management concept
Investing Articles

Here’s why I think the Lloyds share price is undervalued but still not worth me buying

Oliver Rodzianko reckons the Lloyds share price is not appealing enough for him to make a long-term value investment in…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Insiders are buying Rolls-Royce shares! Should I do the same

Two directors have been buying Rolls-Royce shares since the start of the year. Does that mean the rally has further…

Read more »

Senior woman potting plant in garden at home
Investing Articles

How I’d invest a £100K SIPP to target £8K in dividends annually

Christopher Ruane sets out some principles he adopts when investing his SIPP and explains how he would aim for a…

Read more »